ekonominyheter

TranslateRSSMobil
Amgen's Ovarian Cancer Drug Fails To Meet Endpoints

Amgen's Ovarian Cancer Drug Fails To Meet Endpoints

Wall Street Journal 4/11 11:51

Amgen said that a late-stage trial of its ovarian cancer treatment, trebananib, failed to significantly improve patient survival.

Till artikeln

Ekonomi Nyheter .se - Innehåll

 

 

 

 

DMCA.com Protection Status